ACLY抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using ACLY mouse mAb against HeLa (1), NIH3T3 (2), C6 (3), COS7 (4), and Raji (5) cell lysate.    

  
  

•  

   

     Western blot analysis using ACLY mouse mAb against PC-12(1)Raw264.7(2)NIH/3T3(3)NRK(4)C6(5)F9(6)COS-7(7)CHO3D10(8)cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using ACLY mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Immunofluorescence analysis of NIH/3T3 cells using ACLY mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using ACLY mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using ACLY mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissues using ACLY mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Mouse liver(A) Mouse kidney(B) using ACLY mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rat liver(A) Rat kidney(B) using ACLY mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rabbit liver(A) Rabbit kidney(B) using ACLY mouse mAb with DAB staining.    

  
  

ACLY (ATP-citrate lyase) is a key metabolic enzyme that catalyzes the conversion of citrate and coenzyme A into acetyl-CoA and oxaloacetate, linking carbohydrate metabolism to lipid synthesis. Acetyl-CoA serves as a critical precursor for fatty acid and cholesterol biosynthesis, making ACLY essential in cellular energy homeostasis and proliferation. Dysregulation of ACLY is implicated in metabolic disorders, cancer, and cardiovascular diseases, as its overexpression enhances lipogenesis in tumors and contributes to hyperlipidemia.

ACLY antibodies are immunological tools designed to detect, quantify, or inhibit ACLY protein in research and diagnostic contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study ACLY expression patterns in tissues or cell lines, particularly in cancer metabolism studies. Specific antibodies may target distinct epitopes, including phosphorylated forms (e.g., at Ser455), to assess activation states regulated by signaling pathways like AKT.

Therapeutic interest in ACLY has surged due to its role as a druggable target; inhibitors like bempedoic acid (ETC-1002) are approved for lowering LDL cholesterol. ACLY antibodies thus also support drug development by validating target engagement or monitoring biomarker responses. Their applications span basic research on metabolic reprogramming, clinical biomarker discovery, and preclinical evaluation of metabolic therapies.